Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Surgery Partners (SGRY) Other Operating Expenses (2016 - 2025)

Surgery Partners (SGRY) has disclosed Other Operating Expenses for 11 consecutive years, with -$5.1 million as the latest value for Q3 2025.

  • Quarterly Other Operating Expenses fell 920.0% to -$5.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$7.3 million through Dec 2025, down 1012.5% year-over-year, with the annual reading at -$7.3 million for FY2025, 1012.5% down from the prior year.
  • Other Operating Expenses hit -$5.1 million in Q3 2025 for Surgery Partners, down from -$2.2 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $32.8 million in Q1 2022 to a low of -$5.1 million in Q3 2025.
  • Historically, Other Operating Expenses has averaged $1.1 million across 4 years, with a median of -$2.2 million in 2025.
  • Biggest five-year swings in Other Operating Expenses: soared 160.0% in 2024 and later plummeted 920.0% in 2025.
  • Year by year, Other Operating Expenses stood at -$3.5 million in 2022, then grew by 28.57% to -$2.5 million in 2023, then soared by 80.0% to -$500000.0 in 2024, then tumbled by 920.0% to -$5.1 million in 2025.
  • Business Quant data shows Other Operating Expenses for SGRY at -$5.1 million in Q3 2025, -$2.2 million in Q1 2025, and -$500000.0 in Q3 2024.